02:05:54 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2023-07-14 13:58:50

CS MEDICA A/S ("CS MEDICA" or the "Company"), a MedTech company specializing in Cannabis and pain management, is thrilled to announce the establishment of CANNORDIC India Pvt. Ltd is final. The Indian subsidiary is located at B-007, Param Tower CHS Ltd, Raghunath Nagar, Survewadi, Thane West-400604.

On April 14, 2023, the Company announced that its board of directors approved setting up the subsidiary in India. CANNORDIC India Pvt. Ltd. marks a significant milestone in its expansion strategy, solidifying its commitment to the Indian market and the rest of APAC.

With the vision to improve people's quality of life by merging innovation, science, and nature within healthcare, CANNORDIC India Pvt. Ltd. aims to introduce its cutting-edge medical devices with CBD, complying with all regulatory requirements and ensuring the availability of its esteemed CBD product portfolio in India.

The Local Managing Director, Kamlesh Vora, expressed his enthusiasm, stating, "We are very pleased to announce the establishment of our Indian company. This move allows us to bring our innovative CBD products to the Indian market and cater to the evolving needs of consumers."

Overseas Managing Director, and CEO of CS MEDICA A/S, Lone Henriksen, affirms, "We see great growth potential in India, especially considering the country's strength within the pharmaceutical industry. This expansion will enable us to serve our customers better, being individuals with symptoms and local strategic business partners, and aim for sustainable growth in the Indian pharmaceutical sector."

Cannordic India Pvt. Ltd. is dedicated to complying with all regulatory requirements and ensuring the availability of its esteemed CBD product portfolio in India. Through strategic partnerships and collaboration with local stakeholders, the company aims to foster sustainable growth in the Indian pharmaceutical sector.

The establishment of CANNORDIC India Pvt. Ltd. activates the start of registration of the product portfolio, with an estimated lead time from 3,5 months.